Herpes Labialis (Oral Herpes) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) – Pipeline Review, H2 2017’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)

The report reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Herpes Labialis (Oral Herpes) therapeutics and enlists all their major and minor projects

The report assesses Herpes Labialis (Oral Herpes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AiCuris GmbH & Co KG

Beech Tree Labs Inc

NanoViricides Inc

Onxeo SA

Shulov Innovative Science Ltd

Vironova AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Herpes Labialis (Oral Herpes) - Overview 6

Herpes Labialis (Oral Herpes) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Herpes Labialis (Oral Herpes) - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 20

AiCuris GmbH & Co KG 20

Beech Tree Labs Inc 20

NanoViricides Inc 20

Onxeo SA 21

Shulov Innovative Science Ltd 21

Vironova AB 21

Herpes Labialis (Oral Herpes) - Drug Profiles 23

acyclovir - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Aspidasept - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

B-220 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

BTL-TMLHSV - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

herpes simplex virus [type 1, 2] vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

pritelivir - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecule for Cold Sores - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

squaric acid dibutyl ester - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ZEP-3 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Herpes Labialis (Oral Herpes) - Dormant Projects 37

Herpes Labialis (Oral Herpes) - Discontinued Products 38

Herpes Labialis (Oral Herpes) - Product Development Milestones 39

Featured News & Press Releases 39

Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes 39

May 24, 2017: Cold Sore Treatment Developed by Squarex Shown Effective by Immunotherapy Study 39

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes 40

Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada 40

Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 41

Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 41

May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 42

Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 42

Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 43

Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 43

May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 44

Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 44

Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 45

Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 45

Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Herpes Labialis (Oral Herpes) – Pipeline by AiCuris GmbH & Co KG, H2 2017 20

Herpes Labialis (Oral Herpes) – Pipeline by Beech Tree Labs Inc, H2 2017 20

Herpes Labialis (Oral Herpes) – Pipeline by NanoViricides Inc, H2 2017 21

Herpes Labialis (Oral Herpes) – Pipeline by Onxeo SA, H2 2017 21

Herpes Labialis (Oral Herpes) – Pipeline by Shulov Innovative Science Ltd, H2 2017 21

Herpes Labialis (Oral Herpes) – Pipeline by Vironova AB, H2 2017 22

Herpes Labialis (Oral Herpes) – Dormant Projects, H2 2017 37

Herpes Labialis (Oral Herpes) – Discontinued Products, H2 2017 38

List of Figures

List of Figures

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Targets, H2 2017 12

Number of Products by Stage and Targets, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports